Theralase Technologies Inc. V.TLT

News release!

[coalbet]

Theralase has to change up the news releases and not be so preditable. Try a good one on Friday and catch the short positions going into the weekend. Those short read this like a book.

[consultant99]

I'd settle for any positive PR at this point. But if you are asking...How about a frank assessment of the phase 2 trial, the expected path and timeframe going forward and how the company is going to monetize the treatment. I care less from a scientific perspective and more from a business viewpoint in as my underlying assumption is the treatment works. In other words what's the plan?

[coalbet]

Big money if we get it. While no US price is known at this time, based on the estimates derived from single-arm trials of patient benefits from delay of metastasis and need for cystectomy, ICER calculates annual health-benefit price benchmark ranges of approximately $121,000-$201,000* for nadofaragene firadenovec and $93,000-$162,000 for oportuzumab monatox —

[coalbet]

BOSTON, January 15, 2021 – The Institute for Clinical and Economic Review (ICER) today issued a revised Final Evidence Report that corrects a data entry error within the cost-effectiveness analysis of nadofaragene firadenovec (Adstiladrin®, FKD Therapies Oy and FerGene) for the treatment of non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus

[Eoganacht]

Some time ago Theralase estimated it's charge for a NMIBC treatment could be around $50,000. It seems a charge of from $158,600 - $262,000 could be justified.

[CAinPlap]

I guess CFO of a biotech is not in my future. I could not in good conscience charge someone a quarter million to stay alive just because that is the going rate or "because I can". So are we dealing with profit takers or shorters/manipulators causing the drop today?

[Eoganacht]

How does one go about determining a fair rate of return from a life-saving treatment? A lot of money needs to be recouped from researching and developing the treatment and shareholders need to be compensated for their investment, otherwise why would anyone invest? Or develop treatments? On the other hand, gouging the sick to line your pockets is not acceptable. The original figure of $50,000 from

[Rumpl3StiltSkin]

I think this is a great question. We have seen major price inflation in medicine over the last 50 or so years. I think part of the TLT strategy for starting with NMIBC was to charge a premium against US Medicare and or US insurance companies, which are paying the high prices. So getting this approved through the FDA is key.  In Canada It is whatever deal $$ TLT can strike with their

[CAinPlap]

I hope we go with the 50k per patient rather than a whatever the market will bear approach even if it means less to me as a shareholder. Another interesting decision to be made by patients is would I rather spend a million dollars to live another 4 years or die today and leave the million to my kids? Or worse, do you sell the house you spent a lifetime paying for for a few extra years?

[gojotv!]

My bet it's shorters/manipulators causing the drop. The first shares sold at $0.31 today, then someone posted like 80k for sale at $0.295.... If you were profit-taking, why would you lower your price? You'd put your shares up, and let them come, no? Clear manipulation.

[gojotv!]

Besides its high cost, Adstiladrin doesn't appear to be usable in other cancer applications such as glioblastoma and lung. This whole story is a lot of "meh" to me, but pat yourself on the back if you managed to shake some stop losses and get cheap shares. And when efficacy rates are no longer impaired by poor application, TLD-1433 will be the clear front runner in this space! GLTA